Stable angina pectoris: the medical management of symptomatic myocardial ischemia
1The Mount Sinai and University Health Network Hospitals, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. john.parker@uhn.ca
Insights
Stable angina management focuses on medical therapy to improve symptoms and exercise capacity. Treatment choices depend on individual patient conditions, with several effective anti-anginal agents available.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) is a major cause of death and illness.
- Advances in revascularization have transformed CAD management.
- Medical management of stable angina remains crucial.
Purpose of the Study:
- To review the medical management of symptomatic, stable angina.
- To summarize treatment and prevention strategies for myocardial ischemia.
- To discuss the role of anti-anginal agents in CAD.
Main Methods:
- Review of established anti-anginal agent classes: organic nitrates, beta-blockers, and calcium channel blockers.
- Discussion of individualized treatment approaches based on patient comorbidities.
- Exploration of emerging anti-anginal therapies.
Main Results:
- Organic nitrates, beta-blockers, and calcium channel blockers effectively improve symptoms and exercise capacity in stable angina.
- Patient comorbidities significantly influence the selection of anti-anginal agents.
- Combination therapy may be beneficial but requires individualization.
Conclusions:
- Medical management is key for symptomatic, stable angina.
- Prognosis for patients with stable angina is generally excellent.
- Effective symptom relief may preclude the need for invasive procedures.
Abstract:
Coronary artery disease (CAD) remains an important cause of morbidity and mortality and is a serious public health problem. Over the last 4 decades there have been dramatic advances in the both the prevention and treatment of CAD. The management of CAD was revolutionized by the development of effective surgical and percutaneous revascularization techniques. In this review we discuss the importance of the medical management of symptomatic, stable angina. Medical management approaches to both the treatment and prevention of symptomatic myocardial ischemia are summarized. In Canada, organic nitrates, β-adrenergic blocking agents, and calcium channel antagonists have been available for the therapy of angina for more than 25 years. All 3 classes are of proven benefit in the improvement of symptoms and exercise capacity in patients with stable angina. Although there is no clear first choice within these classes of anti-anginal agents, the presence of prior or concurrent conditions (for example, prior myocardial infarction and/or hypertension) plays an important role in the choice of anti-anginal class in individual patients. For some patients, combinations of different anti-anginal agents can be effective; however it is recommended that this approach be individualized. Although not currently available in Canada, other classes of anti-anginal agents have been developed; their mechanism of action and clinical efficacy is discussed. Patients with stable angina have an excellent prognosis. Patients in this category who obtain relief from symptomatic myocardial ischemia may do well without invasive intervention.
Related Concept Videos
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:14Myocarditis III: Medical Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Angina II: Classification
01:30Angina I: Introduction